匯思太平洋(08147.HK)發行2000萬港元可換股債
格隆匯6月17日丨匯思太平洋(08147.HK)公吿,於2021年6月17日,公司與認購方訂立認購協議,內容有關發行金總額為2000萬港元可換股債券。
可換股債券按初步換股價每股換股股份0.12港元(可予調整)悉數轉換後,將予發行合共166,666,666股換股股份,相當於本公司現有已發行股本約16.2%及經發行換股股份擴大後本公司已發行股本約13.9%。換股股份將根據一般授權配發及發行。
認購事項所得款額總額及所得款額淨額將分別為2000萬港元及約2000萬港元。本集團擬將所得款額淨額約2000萬港元用於償還本集團未償還負債。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.